IQVIA (IQV) 10-Q 29 Jul 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 22, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	Q
Entity Registrant Name	Quintiles Transnational Holdings Inc.
Entity Central Index Key	1,478,242
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		122,706,672

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Service revenues	$ 1,074,366	$ 1,035,476	$ 2,104,340	$ 2,040,764
Reimbursed expenses	369,161	305,554	686,780	608,112
Total revenues	1,443,527	1,341,030	2,791,120	2,648,876
Costs of revenue, service costs	683,845	674,514	1,345,672	1,318,236
Costs of revenue, reimbursed expenses	369,161	305,554	686,780	608,112
Selling, general and administrative	225,898	219,014	445,504	438,256
Restructuring costs	6,234	948	11,558	1,956
Income from operations	158,389	141,000	301,606	282,316
Interest income	(1,459)	(994)	(2,329)	(2,249)
Interest expense	25,487	24,799	50,827	49,502
Loss on extinguishment of debt	7,780		7,780
Other expense (income), net	11,659	3,056	8,798	(1,788)
Income before income taxes and equity in earnings of unconsolidated affiliates	114,922	114,139	236,530	236,851
Income tax expense	31,700	32,400	67,788	69,789
Income before equity in earnings of unconsolidated affiliates	83,222	81,739	168,742	167,062
Equity in earnings of unconsolidated affiliates	1,725	3,371	2,636	8,262
Net income	84,947	85,110	171,378	175,324
Net loss (income) attributable to noncontrolling interests	4	10	(29)	(21)
Net income attributable to Quintiles Transnational Holdings Inc.	$ 84,951	$ 85,120	$ 171,349	$ 175,303
Earnings per share attributable to common shareholders:
Basic	$ 0.69	$ 0.66	$ 1.38	$ 1.35
Diluted	$ 0.67	$ 0.64	$ 1.35	$ 1.32
Weighted average common shares outstanding:
Basic	123,834	128,979	124,169	129,439
Diluted	126,536	132,042	126,995	132,541

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 84,947	$ 85,110	$ 171,378	$ 175,324
Unrealized gains (losses) on marketable securities, net of income taxes of $9, ($1,498), ($95) and ($290)	14	(2,393)	(151)	(463)
Unrealized gains (losses) on derivative instruments, net of income taxes of $327, $17, ($713) and ($108)	3,444	928	(220)	1,250
Foreign currency translation, net of income taxes of $146, $0, ($2,665) and $0	13,007	3,861	(17,005)	4,164
Reclassification adjustments:
Gains on marketable securities included in net income, net of income taxes of ($1,927)				(3,077)
Losses on derivative instruments included in net income, net of income taxes of $1,590, $736, $3,246 and $1,530	3,502	121	7,338	496
Amortization of prior service costs and losses included in net income, net of income taxes of $85, $72, $168 and $144	147	121	287	241
Comprehensive income	105,061	87,748	161,627	177,935
Comprehensive loss (income) attributable to noncontrolling interests	1	9	(29)	(12)
Comprehensive income attributable to Quintiles Transnational Holdings Inc.	$ 105,062	$ 87,757	$ 161,598	$ 177,923

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement Of Income And Comprehensive Income [Abstract]
Unrealized gains (losses) on marketable securities, income taxes	$ 9	$ (1,498)	$ (95)	$ (290)
Unrealized gains (losses) on derivative instruments, income taxes	327	17	(713)	(108)
Foreign currency translation, income taxes	146	0	(2,665)	0
Gains on marketable securities included in net income, income taxes				(1,927)
Losses on derivative instruments included in net income, income taxes	1,590	736	3,246	1,530
Amortization of prior service costs and losses included in net income, income taxes	$ 85	$ 72	$ 168	$ 144

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 803,615	$ 867,358
Restricted cash	3,146	2,882
Trade accounts receivable and unbilled services, net	1,089,439	975,255
Prepaid expenses	57,454	44,628
Deferred income taxes	115,962	118,515
Income taxes receivable	64,550	45,357
Other current assets and receivables	85,676	92,088
Total current assets	2,219,842	2,146,083
Property and equipment, net	176,773	190,297
Investments in debt, equity and other securities	34,258	34,503
Investments in and advances to unconsolidated affiliates	37,445	31,508
Goodwill	463,610	464,434
Other identifiable intangibles, net	263,217	280,243
Deferred income taxes	34,694	35,972
Deposits and other assets	111,945	112,913
Total assets	3,341,784	3,295,953
Current liabilities:
Accounts payable and accrued expenses	758,407	842,387
Unearned income	502,477	543,305
Income taxes payable	32,662	55,694
Current portion of long-term debt and obligations held under capital leases	48,510	826
Other current liabilities	11,752	29,688
Total current liabilities	1,353,808	1,471,900
Long-term debt and obligations held under capital leases, less current portion	2,440,972	2,282,612
Deferred income taxes	57,925	61,797
Other liabilities	190,757	183,656
Total liabilities	$ 4,043,462	$ 3,999,965
Commitments and contingencies
Shareholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 122,644 and 124,129 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	$ 28,520	$ 143,828
Accumulated deficit	(661,434)	(788,798)
Accumulated other comprehensive loss	(68,842)	(59,091)
Deficit attributable to Quintiles Transnational Holdings Inc.’s shareholders	(701,756)	(704,061)
Noncontrolling interests	78	49
Total shareholders’ deficit	(701,678)	(704,012)
Total liabilities and shareholders’ deficit	$ 3,341,784	$ 3,295,953

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	122,644,000	124,129,000
Common stock, shares outstanding	122,644,000	124,129,000

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities :
Net income	$ 171,378	$ 175,324
Adjustments to reconcile net income to cash (used in) provided by operating activities:
Depreciation and amortization	60,340	58,933
Amortization of debt issuance costs and discount	5,800	3,191
Amortization of accumulated other comprehensive loss on terminated interest rate swaps	1,651
Share-based compensation	20,321	15,601
Earnings from unconsolidated affiliates	(2,603)	(8,239)
Loss (gain) on investments, net	5	(5,114)
Benefit from deferred income taxes	(375)	(1,173)
Excess income tax benefits from share-based award activities	(29,565)	(8,613)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	(177,494)	(61,568)
Change in other operating assets and liabilities	(63,028)	(129,645)
Net cash (used in) provided by operating activities	(13,570)	38,697
Investing activities:
Acquisition of property, equipment and software	(31,924)	(35,832)
Proceeds from sale of equity securities		5,861
Investments in and advances to unconsolidated affiliates, net of payments received	(3,431)	(2,336)
Termination of interest rate swaps	(10,981)
Other	870	(701)
Net cash used in investing activities	(45,466)	(33,008)
Financing activities:
Proceeds from issuance of debt	2,248,500
Payment of debt issuance costs	(21,857)
Repayment of debt and principal payments on capital lease obligations	(2,035,051)	(466)
Stock issued under employee stock purchase and option plans	45,308	11,313
Repurchase of common stock	(250,000)	(165,131)
Payroll taxes remitted on repurchase of stock options		(8,415)
Excess income tax benefits from share-based award activities	29,565	8,613
Net cash provided by (used in) financing activities	16,465	(154,086)
Effect of foreign currency exchange rate changes on cash	(21,172)	6,722
Decrease in cash and cash equivalents	(63,743)	(141,675)
Cash and cash equivalents at beginning of period	867,358	778,143
Cash and cash equivalents at end of period	$ 803,615	$ 636,468

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Reclassifications Certain immaterial prior period amounts have been reclassified to conform to current presentation including the reclassification of debt issuance costs related to non-revolving debt from deposits and other assets to a direct reduction to the carrying amount of the long-term debt on the balance sheet. These changes had no effect on previously reported total revenues, net income, comprehensive income, shareholders’ deficit or cash flows. Recently Issued Accounting Standards In February 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which changes the analysis in determining whether an entity is considered a variable interest entity (“VIE”) and the identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity’s consolidated financial statements. The Company will adopt the new accounting guidance on January 1, 2016, as required. The Company is currently evaluating the impact of this update on its consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition and changes in assets and liabilities that result from contracts with customers. Companies have an option to use either a retrospective approach or a cumulative effect adjustment approach to implement the new guidance. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new guidance. Research and Development Costs In January 2010, the Company entered into a collaboration agreement with a related party, HUYA Bioscience International, LLC (“HUYA”), to fund up to $2.3 million of its research and development activity for a specific compound. Under the agreement, the Company had the potential to receive additional consideration which contractually would not exceed $16.5 million excluding interest if certain events had occurred. In February 2015, the Company and HUYA agreed to terminate the collaboration agreement. In connection with the termination, HUYA paid the Company $5.0 million to satisfy all of HUYA’s various payment obligations under the collaboration agreement.

Employee Stock Compensation

Employee Stock Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Employee Stock Compensation	2. Employee Stock Compensation The Company granted the following share-based awards: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock options 53,200 335,100 976,900 1,359,600 Stock appreciation rights — — 176,200 176,800 Restricted stock units 10,389 36,500 237,210 36,500 Performance units — — 51,977 — The Company had the following share-based awards outstanding: June 30, 2015 December 31, 2014 Stock options 7,548,947 9,124,954 Stock appreciation rights 557,513 418,801 Restricted stock units 328,611 93,667 Performance units 51,977 — The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Expected volatility 28 – 37% 31 – 43% 28 – 41% 31 – 43% Weighted average expected volatility 31% 37% 35% 37% Expected dividends 0.0% 0.0% 0.0% 0.0% Expected term (in years) 3.7 – 6.7 3.7 – 6.7 3.7 – 6.7 3.7 – 6.7 Risk-free interest rate 1.16 – 2.00% 1.15 – 2.13% 1.06 – 2.00% 0.99 – 2.21% In March 2015, the Company awarded performance units that contain both service and performance based vesting criteria. Vesting occurs if the recipient remains employed and depends on the degree to which the Company achieves certain cumulative adjusted diluted earnings per share goals during a three-year performance period (as defined in the award agreements). The fair value of these awards is equal to the closing price of the Company’s common stock on the grant date. In November 2013, the Company’s Board of Directors (the “Board”) approved an Employee Stock Purchase Plan (“ESPP”) which was approved by the Company’s shareholders in May 2014. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary to be applied toward the purchase of full shares of the Company’s common stock on the last day of the offering period. Offering periods under the ESPP are six months in duration. The first two offering periods for the ESPP began March 1, 2014 and September 1, 2014, respectively. In November 2014, the ESPP was amended to change the start of the offering periods to begin on April 1 and October 1 of each year, beginning April 1, 2015. Participating employees purchase shares on the last day of each offering period at a discount of 15% of the closing price of the common stock on such date as reported on the New York Stock Exchange. During the six months ended June 30, 2015, the Company issued 38,449 shares of common stock for purchases under the ESPP. The Company recognized share-based compensation expense of $10.7 million and $8.4 million during the three months ended June 30, 2015 and 2014, respectively, and $20.3 million and $15.6 million during the six months ended June 30, 2015 and 2014, respectively.

Concentration of Credit Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2015
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	3. Concentration of Credit Risk No customer accounted for 10% or more of consolidated service revenues for the three and six months ended June 30, 2015 or 2014.

Accounts Receivable and Unbille

Accounts Receivable and Unbilled Services	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Accounts Receivable and Unbilled Services	4. Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consist of the following (in thousands): June 30, 2015 December 31, 2014 Trade: Billed $ 506,239 $ 444,941 Unbilled services 584,851 532,312 1,091,090 977,253 Allowance for doubtful accounts (1,651 ) (1,998 ) $ 1,089,439 $ 975,255

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	5. Goodwill The following is a summary of goodwill by segment for the six months ended June 30, 2015 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2014 $ 346,608 $ 117,826 $ 464,434 Impact of foreign currency fluctuations and other (257 ) (567 ) (824 ) Balance as of June 30, 2015 $ 346,351 $ 117,259 $ 463,610

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	6. Derivatives As of June 30, 2015, the Company held the following derivative positions: (i) forward exchange contracts to protect against foreign exchange movements for certain forecasted foreign currency cash flows related to service contracts and (ii) interest rate swaps to hedge the exposure to variability in interest payments on variable interest rate debt. The Company does not use derivative financial instruments for speculative or trading purposes. As of June 30, 2015, the Company had 15 open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2015 and the first three months of 2016 with notional amounts totaling $100.6 million. These contracts were executed to hedge the risk of the potential volatility in the cash flows resulting from fluctuations in currency exchange rates during the remainder of 2015 and the first three months of 2016. These transactions are accounted for as cash flow hedges, as such, the effective portion of the gain or loss on the contracts is recorded as unrealized gains (losses) on derivatives included in the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit. These hedges are highly effective. Upon expiration of the hedge instruments in 2015 and the first three months of 2016, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in AOCI into earnings. On June 9, 2011, the Company entered into six interest rate swaps which expired between September 30, 2013 and March 31, 2016 in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. During May 2015, in conjunction with the debt refinancing described in Note 8, the Company terminated the remaining open interest rate swaps for a cash payment to the counterparty of $12.4 million which included $1.4 million of accrued interest. Since the hedged forecasted cash transactions continue to be probable of occurring, the accumulated loss ($9.3 million at June 30, 2015) related to the terminated interest rate swaps in AOCI will be reclassified to earnings as a component of interest expense in the same periods as the hedged forecasted transactions occur over the next nine months. On June 3, 2015, the Company entered into seven forward starting interest rate swaps with a notional value of $440.0 million in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. Interest on the swaps begins to accrue on June 30, 2016 and the interest rate swaps expire between March 31, 2017 and March 31, 2020. The critical terms of the interest rate swaps were substantially the same as those of the Company’s senior secured credit facilities, including quarterly interest settlements. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments, and these hedges are deemed to be highly effective. As such, changes in the fair value of these derivative instruments are recorded as unrealized gains (losses) on derivatives included in AOCI. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the condensed consolidated statements of income. These payments, together with the variable rate of interest incurred on the underlying debt, result in a fixed rate of interest of 2.1% plus the applicable margin on the affected borrowings. These interest rate swaps in conjunction with the Company’s Senior Notes, as defined below, will result in a debt mix of approximately 50% fixed rate debt and 50% variable rate debt. The Company does not expect to recognize any gains or losses from the interest rate swaps in its income during the next 12 months. The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification June 30, 2015 December 31, 2014 Foreign exchange forward contracts Other current assets $ 2,325 $ — Foreign exchange forward contracts Other current liabilities $ 571 $ 4,635 Interest rate swaps Other current liabilities $ 1,832 $ 14,424 The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Foreign exchange forward contracts $ 8,078 $ (335 ) $ 6,389 $ (1,144 ) Interest rate swaps 785 2,137 3,262 4,312 Total $ 8,863 $ 1,802 $ 9,651 $ 3,168

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: · Level 1 — Quoted prices in active markets for identical assets or liabilities. · Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. · Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of June 30, 2015 (in thousands): Level 1 Level 2 Level 3 Total Assets: Marketable equity securities $ 585 $ — $ — $ 585 Foreign exchange forward contracts — 2,325 — 2,325 Total $ 585 $ 2,325 $ — $ 2,910 Liabilities: Foreign exchange forward contracts $ — $ 571 $ — $ 571 Interest rate swaps — 1,832 — 1,832 Contingent consideration — — 7,338 7,338 Total $ — $ 2,403 $ 7,338 $ 9,741 Below is a summary of the valuation techniques used in determining fair value: Marketable equity securities — The Company values marketable equity securities utilizing quoted market prices. Foreign exchange forward contracts — The Company values foreign exchange forward contracts using quoted market prices for identical instruments in less active markets or using other observable inputs. Interest rate swaps — The Company values interest rate swaps using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating forecasts and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended June 30 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses and Other Liabilities 2015 2014 Balance as of January 1 $ 1,452 $ 13,014 Revaluations included in earnings 5,886 186 Balance as of June 30 $ 7,338 $ 13,200 The revaluations for the contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income. Non-recurring Fair Value Measurements Certain assets are carried on the accompanying condensed consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include cost and equity method investments and loans that are written down to fair value for declines which are deemed to be other-than-temporary, and goodwill and identifiable intangible assets which are tested for impairment annually and when a triggering event occurs. As of June 30, 2015, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $797.9 million were identified as Level 3. These assets are comprised of cost and equity method investments of $71.1 million, goodwill of $463.6 million and other identifiable intangibles, net of $263.2 million. The Company has unfunded cash commitments totaling approximately $41.6 million related to its cost and equity method investments as of June 30, 2015.

Credit Arrangements

Credit Arrangements	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Credit Arrangements	8. Credit Arrangements The following is a summary of the Company’s revolving credit facilities at June 30, 2015: Facility Interest Rates $500.0 million (first lien revolving credit facility) London Interbank Offer Rate (“LIBOR”) (0.28% at June 30, 2015) plus 1.75% $25.0 million (receivables financing facility) LIBOR Market Index Rate (0.19% at June 30, 2015) plus 0.85% to 1.35% depending upon the Company’s debt rating £10.0 million (approximately $15.7 million) general banking facility with a European headquartered bank Bank’s base rate (0.5% at June 30, 2015) plus 1% The Company did not have any outstanding borrowings under any of the revolving credit facilities at June 30, 2015 or December 31, 2014. At June 30, 2015, there were bank guarantees totaling approximately £3.8 million (approximately $6.0 million) issued against the availability of the general banking facility with a European-headquartered bank through its operations in the United Kingdom. Long-term debt consists of the following (in thousands): June 30, 2015 December 31, 2014 4.875% Senior Notes due 2023 $ 800,000 $ — Term Loan A due 2020 (LIBOR plus 1.75%, or 2.03% at June 30, 2015) 850,000 — Term Loan B due 2022 (the greater of LIBOR or 0.75% plus 2.50%, or 3.25% at June 30, 2015) 600,000 — Term Loan B-3 due 2018 (the greater of three month LIBOR or 1.25% plus 2.50%, or 3.75% at December 31, 2014) — 2,030,606 Receivables financing facility due 2018 (LIBOR 0.19% plus 1.05%, or 1.24% at June 30, 2015) 275,000 275,000 2,525,000 2,305,606 Less: unamortized discount (26,072 ) (12,379 ) Less: unamortized debt issuance costs (9,469 ) (9,879 ) Less: current portion (48,500 ) (750 ) $ 2,440,959 $ 2,282,598 Contractual maturities of long-term debt at June 30, 2015 are as follows (in thousands): 2015 $ 24,250 2016 48,500 2017 48,500 2018 323,500 2019 48,500 2020 664,750 Thereafter 1,367,000 $ 2,525,000 The estimated fair value of the Company’s long-term debt approximates its carrying value as of June 30, 2015 and December 31, 2014. The estimated fair value of the long-term debt is primarily based on rates in which the debt is traded among banks. Refinancing Transaction On May 12, 2015, Quintiles Transnational Corp. (“Quintiles Transnational”), a wholly-owned subsidiary of the Company, entered into new senior secured credit facilities (the “New Facilities”) totaling $1.95 billion. The New Facilities consist of a five-year $500.0 million revolving credit facility (the “New Revolver”) and $1.45 billion of term loans ($850 million in Term Loan A due 2020 (“Term Loan A”) and $600 million in Term Loan B due in 2022 (“Term Loan B”)). In addition, Quintiles Transnational issued $800 million of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) in a private placement. The New Facilities and the Senior Notes are referred to collectively as the “New Debt.” Annual maturities on the Term Loan A and the Term Loan B are 5% and 1%, respectively, of the respective original principal amount with the remaining balance to be repaid on their respective maturity dates. Beginning with the fiscal year ending December 31, 2016, the Company will be required to make mandatory repayments on Term Loan A and Term Loan B of 50% of excess cash flow (as defined in the credit agreement covering the New Facilities, subject to a reduction to 25% or 0% depending upon the Company’s leverage ratio). Mandatory repayments will be allocated pro rata between Term Loan A and Term Loan B (subject to increases in the amount of Term Loan A repayments with amounts declined by Term Loan B lenders), and applied, first, to reduce the next eight quarterly amortization installments in direct order of maturity, and, second, to reduce all remaining amortization installments pro rata. The Company will also be required to make mandatory repayments with 100% of the net cash proceeds of certain asset dispositions, subject to thresholds and reinvestment rights. The new senior secured credit facilities arrangements are collateralized by substantially all of the assets of Quintiles Transnational and the assets of Quintiles Transnational’s domestic subsidiaries including 100% of the equity interests of substantially all of Quintiles Transnational’s domestic subsidiaries and 65% of the equity interests of substantially all of the first-tier foreign subsidiaries of Quintiles Transnational and its domestic subsidiaries. Interest on the Senior Notes is paid semiannually on May 15 and November 15 (beginning November 15, 2015) of each year until maturity. The Senior Notes are unsecured senior obligations of Quintiles Transnational and are effectively subordinated in right of payment to all secured obligations of Quintiles Transnational, to the extent of the value of any collateral. The Company used the proceeds from the New Debt (i) to repay the then-outstanding Term Loan B-3 which was due in 2018, (ii) to pay related fees and expenses including $11.0 million of breakage fees associated with the terminated interest rate swaps discussed further in Note 6, and iii) for general corporate purposes including the share repurchase discussed further in Note 9. In connection with this refinancing transaction, in the second quarter of 2015 the Company recognized a $7.8 million loss on extinguishment of debt which included $1.1 million of unamortized debt issuance costs, $1.3 million of unamortized discount and $5.4 million of related fees and expenses. Debt Covenants The Company’s long-term debt agreements contain usual and customary restrictive covenants that, among other things, place limitations on its ability to declare dividends and make other restricted payments; prepay, redeem or purchase debt; incur liens; make loans and investments; incur additional indebtedness; amend or otherwise alter debt and other material documents; engage in mergers, acquisitions and asset sales; transact with affiliates; and engage in businesses that are not related to the Company’s existing business. In the six months ended June 30, 2015, the Company was in compliance with its debt covenants.

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Shareholders' Deficit	9. Shareholders’ Deficit Equity Repurchase Program On October 30, 2013, the Company’s Board of Directors (the “Board”) approved an equity repurchase program (the “Repurchase Program”) authorizing the repurchase of up to $125.0 million of either the Company’s common stock or vested in-the-money employee stock options, or a combination thereof. In April 2015, the Board increased the share repurchase authorization under the Repurchase Program by $300.0 million. The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock or vested in-the-money employee stock options, and it could be modified, suspended or discontinued at any time. The Repurchase Program for vested in-the-money employee stock options expired in November 2013. The Repurchase Program for common stock does not have an end date. On May 19, 2015, the Company completed the repurchase of 3,855,050 shares of its common stock for $64.85 per share for an aggregate purchase price of approximately $250.0 million. As of June 30, 2015, the Company has remaining authorization under the Repurchase Program to repurchase up to $109.5 million of its common stock.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2015
Restructuring And Related Activities [Abstract]
Restructuring	10. Restructuring In February 2015 , the Board Since February 2015, the Company has recognized approximately $8.1 million, $2.5 million and $396,000 of restructuring costs related to this plan for activities in the Product Development segment, Integrated Healthcare Services segment and corporate activities, respectively. To date, all of the restructuring costs are related to severance costs. Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures reviewed by management. The following amounts were recorded for the February 2015 restructuring plan and the restructuring plans initiated in prior years (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2014 $ 5,478 $ 605 $ 6,083 Expense, net of reversals 10,664 894 11,558 Adjustment for deferred rent — 594 594 Payments (10,354 ) (471 ) (10,825 ) Foreign currency translation (57 ) — (57 ) Balance at June 30, 2015 $ 5,731 $ 1,622 $ 7,353 The Company expects the majority of the restructuring accruals at June 30, 2015 will be paid in 2015.

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2015
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	11. Employee Benefit Plans Defined Benefit Plans The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Service cost $ 4,251 $ 3,391 $ 7,865 $ 6,678 Interest cost 866 1,003 1,733 1,990 Expected return on plan assets (861 ) (942 ) (1,714 ) (1,870 ) Amortization of prior service costs — 20 — 40 Amortization of actuarial losses 232 173 455 345 $ 4,488 $ 3,645 $ 8,339 $ 7,183 Other As of June 30, 2015 and December 31, 2014, the Company had a severance accrual included in accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets of $4.1 million and $6.3 million, respectively. The Company recognizes obligations associated with severance related to contractual termination benefits at fair value on the date that it is probable that the affected employees will be entitled to the benefit and the amount can reasonably be estimated. The severance accrual is related to cost reduction programs that will result in severance for approximately 270 positions, which are expected to lower operating costs and improve profitability. During the first six months of 2015, the Company recognized approximately $607,000 of net reversals related to these cost reduction programs, primarily as a result of affected individuals transferring into other positions within the Company. Of the $607,000 decrease from net reversals recognized for these cost reduction programs, approximately $581,000 and $26,000 were related to activities in the Product Development segment and Integrated Healthcare Services segment, respectively. The Company expects the majority of the severance accrual at June 30, 2015 will be paid in 2015. The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2014 $ 6,274 Expense, net of reversals (607 ) Payments (1,510 ) Foreign currency translation (21 ) Balance at June 30, 2015 $ 4,136

Comprehensive Income

Comprehensive Income	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Comprehensive Income	12. Comprehensive Income Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Marketable Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2014 $ (55,740 ) $ (272 ) $ (19,059 ) $ (14,519 ) $ 30,499 $ (59,091 ) Other comprehensive (loss) income before reclassifications (19,670 ) (246 ) (933 ) — 3,473 (17,376 ) Reclassification adjustments — — 10,584 455 (3,414 ) 7,625 Balance at June 30, 2015 $ (75,410 ) $ (518 ) $ (9,408 ) $ (14,064 ) $ 30,558 $ (68,842 ) Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Reclassification Adjustments Affected Financial Statement Line Item Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 Marketable securities Other (income) expense, net $ — $ — $ — $ (5,004 ) Total before income taxes — — — (5,004 ) Income tax expense — — — (1,927 ) Total net of income taxes $ — $ — $ — $ (3,077 ) Derivative instruments: Interest rate swaps Interest expense $ 3,090 $ 3,115 $ 6,103 $ 6,195 Foreign exchange forward contracts Service revenues 2,002 (2,258 ) 4,481 (4,169 ) Total before income taxes 5,092 857 10,584 2,026 Income tax benefit 1,590 736 3,246 1,530 Total net of income taxes $ 3,502 $ 121 $ 7,338 $ 496 Defined benefit plans: Amortization of prior service costs See Note 11 $ — $ 20 $ — $ 40 Amortization of actuarial losses See Note 11 232 173 455 345 Total before income taxes 232 193 455 385 Income tax benefit 85 72 168 144 Total net of income taxes $ 147 $ 121 $ 287 $ 241

Segments

Segments	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segments	13. Segments The following table presents the Company’s operations by reportable segment. The Company is managed through two reportable segments, Product Development and Integrated Healthcare Services. Product Development, which primarily serves biopharmaceutical customers engaged in research and development, provides clinical research and clinical trial services. Integrated Healthcare Services provides commercialization services to biopharmaceutical customers and research, analytics, real-world and late phase research, and other services to both biopharmaceutical customers and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of share-based compensation and expenses for corporate overhead functions such as finance, human resources, information technology, facilities and legal. The Company does not allocate restructuring or impairment charges to its segments. Information presented below is in thousands: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Service revenues Product Development $ 786,397 $ 781,187 $ 1,535,926 $ 1,552,015 Integrated Healthcare Services 287,969 254,289 568,414 488,749 Total service revenues 1,074,366 1,035,476 2,104,340 2,040,764 Costs of revenue, service costs Product Development 453,450 465,278 890,872 915,761 Integrated Healthcare Services 230,395 209,236 454,800 402,475 Total costs of revenue, service costs 683,845 674,514 1,345,672 1,318,236 Selling, general and administrative Product Development 156,777 157,552 311,885 317,237 Integrated Healthcare Services 38,845 33,346 76,767 65,622 General corporate and unallocated 30,276 28,116 56,852 55,397 Total selling, general and administrative 225,898 219,014 445,504 438,256 Income from operations Product Development 176,170 158,357 333,169 319,017 Integrated Healthcare Services 18,729 11,707 36,847 20,652 General corporate and unallocated (30,276 ) (28,116 ) (56,852 ) (55,397 ) Restructuring costs (6,234 ) (948 ) (11,558 ) (1,956 ) Total income from operations $ 158,389 $ 141,000 $ 301,606 $ 282,316 Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Depreciation and amortization expense Product Development $ 23,553 $ 23,791 $ 47,429 $ 46,761 Integrated Healthcare Services 5,171 4,854 10,379 9,745 General corporate and unallocated 1,287 1,200 2,532 2,427 Total depreciation and amortization expense $ 30,011 $ 29,845 $ 60,340 $ 58,933

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	14. Earnings Per Share The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Weighted average shares subject to anti-dilutive share-based awards 1,182 1,598 1,112 1,182 Share-based awards will have a dilutive effect under the treasury method only when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	15. Subsequent Event On July 1, 2015, the Company and Quest Diagnostics Incorporated (“Quest”) closed on a joint venture transaction that will combine their respective clinical trials laboratory operations in which the Company owns 60% and Quest owns 40%. The Company believes the combined capabilities will provide customers with globally scaled end-to-end clinical trials laboratory services. The Company will account for the transaction as a business combination and will consolidate the new legal entities in its financial statements with a non-controlling interest for the portion owned by Quest. The Company has not completed the detailed valuations necessary to determine, and therefore is not yet able to disclose, the estimated fair value of the assets acquired, the liabilities assumed and the non-controlling interests.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
Reclassifications	Reclassifications Certain immaterial prior period amounts have been reclassified to conform to current presentation including the reclassification of debt issuance costs related to non-revolving debt from deposits and other assets to a direct reduction to the carrying amount of the long-term debt on the balance sheet. These changes had no effect on previously reported total revenues, net income, comprehensive income, shareholders’ deficit or cash flows.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In February 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which changes the analysis in determining whether an entity is considered a variable interest entity (“VIE”) and the identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity’s consolidated financial statements. The Company will adopt the new accounting guidance on January 1, 2016, as required. The Company is currently evaluating the impact of this update on its consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition and changes in assets and liabilities that result from contracts with customers. Companies have an option to use either a retrospective approach or a cumulative effect adjustment approach to implement the new guidance. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new guidance.
Research and Development Costs	Research and Development Costs In January 2010, the Company entered into a collaboration agreement with a related party, HUYA Bioscience International, LLC (“HUYA”), to fund up to $2.3 million of its research and development activity for a specific compound. Under the agreement, the Company had the potential to receive additional consideration which contractually would not exceed $16.5 million excluding interest if certain events had occurred. In February 2015, the Company and HUYA agreed to terminate the collaboration agreement. In connection with the termination, HUYA paid the Company $5.0 million to satisfy all of HUYA’s various payment obligations under the collaboration agreement.

Employee Stock Compensation (Ta

Employee Stock Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-Based Awards Granted and Outstanding	The Company granted the following share-based awards: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock options 53,200 335,100 976,900 1,359,600 Stock appreciation rights — — 176,200 176,800 Restricted stock units 10,389 36,500 237,210 36,500 Performance units — — 51,977 — The Company had the following share-based awards outstanding: June 30, 2015 December 31, 2014 Stock options 7,548,947 9,124,954 Stock appreciation rights 557,513 418,801 Restricted stock units 328,611 93,667 Performance units 51,977 —
Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued	The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Expected volatility 28 – 37% 31 – 43% 28 – 41% 31 – 43% Weighted average expected volatility 31% 37% 35% 37% Expected dividends 0.0% 0.0% 0.0% 0.0% Expected term (in years) 3.7 – 6.7 3.7 – 6.7 3.7 – 6.7 3.7 – 6.7 Risk-free interest rate 1.16 – 2.00% 1.15 – 2.13% 1.06 – 2.00% 0.99 – 2.21%

Accounts Receivable and Unbil25

Accounts Receivable and Unbilled Services (Tables)	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Accounts Receivable and Unbilled Services	Accounts receivable and unbilled services consist of the following (in thousands): June 30, 2015 December 31, 2014 Trade: Billed $ 506,239 $ 444,941 Unbilled services 584,851 532,312 1,091,090 977,253 Allowance for doubtful accounts (1,651 ) (1,998 ) $ 1,089,439 $ 975,255

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Segment	The following is a summary of goodwill by segment for the six months ended June 30, 2015 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2014 $ 346,608 $ 117,826 $ 464,434 Impact of foreign currency fluctuations and other (257 ) (567 ) (824 ) Balance as of June 30, 2015 $ 346,351 $ 117,259 $ 463,610

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification June 30, 2015 December 31, 2014 Foreign exchange forward contracts Other current assets $ 2,325 $ — Foreign exchange forward contracts Other current liabilities $ 571 $ 4,635 Interest rate swaps Other current liabilities $ 1,832 $ 14,424
Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss)	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Foreign exchange forward contracts $ 8,078 $ (335 ) $ 6,389 $ (1,144 ) Interest rate swaps 785 2,137 3,262 4,312 Total $ 8,863 $ 1,802 $ 9,651 $ 3,168

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of June 30, 2015 (in thousands): Level 1 Level 2 Level 3 Total Assets: Marketable equity securities $ 585 $ — $ — $ 585 Foreign exchange forward contracts — 2,325 — 2,325 Total $ 585 $ 2,325 $ — $ 2,910 Liabilities: Foreign exchange forward contracts $ — $ 571 $ — $ 571 Interest rate swaps — 1,832 — 1,832 Contingent consideration — — 7,338 7,338 Total $ — $ 2,403 $ 7,338 $ 9,741
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended June 30 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses and Other Liabilities 2015 2014 Balance as of January 1 $ 1,452 $ 13,014 Revaluations included in earnings 5,886 186 Balance as of June 30 $ 7,338 $ 13,200

Credit Arrangements (Tables)

Credit Arrangements (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Summary of Company's Credit Facilities	The following is a summary of the Company’s revolving credit facilities at June 30, 2015: Facility Interest Rates $500.0 million (first lien revolving credit facility) London Interbank Offer Rate (“LIBOR”) (0.28% at June 30, 2015) plus 1.75% $25.0 million (receivables financing facility) LIBOR Market Index Rate (0.19% at June 30, 2015) plus 0.85% to 1.35% depending upon the Company’s debt rating £10.0 million (approximately $15.7 million) general banking facility with a European headquartered bank Bank’s base rate (0.5% at June 30, 2015) plus 1%
Schedule of Long-term Debt	Long-term debt consists of the following (in thousands): June 30, 2015 December 31, 2014 4.875% Senior Notes due 2023 $ 800,000 $ — Term Loan A due 2020 (LIBOR plus 1.75%, or 2.03% at June 30, 2015) 850,000 — Term Loan B due 2022 (the greater of LIBOR or 0.75% plus 2.50%, or 3.25% at June 30, 2015) 600,000 — Term Loan B-3 due 2018 (the greater of three month LIBOR or 1.25% plus 2.50%, or 3.75% at December 31, 2014) — 2,030,606 Receivables financing facility due 2018 (LIBOR 0.19% plus 1.05%, or 1.24% at June 30, 2015) 275,000 275,000 2,525,000 2,305,606 Less: unamortized discount (26,072 ) (12,379 ) Less: unamortized debt issuance costs (9,469 ) (9,879 ) Less: current portion (48,500 ) (750 ) $ 2,440,959 $ 2,282,598
Contractual Maturities of Long-term Debt	Contractual maturities of long-term debt at June 30, 2015 are as follows (in thousands): 2015 $ 24,250 2016 48,500 2017 48,500 2018 323,500 2019 48,500 2020 664,750 Thereafter 1,367,000 $ 2,525,000

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2015
Restructuring And Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the February 2015 restructuring plan and the restructuring plans initiated in prior years (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2014 $ 5,478 $ 605 $ 6,083 Expense, net of reversals 10,664 894 11,558 Adjustment for deferred rent — 594 594 Payments (10,354 ) (471 ) (10,825 ) Foreign currency translation (57 ) — (57 ) Balance at June 30, 2015 $ 5,731 $ 1,622 $ 7,353

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2015
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Pension Expenses Related to Defined Benefit Plans	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Service cost $ 4,251 $ 3,391 $ 7,865 $ 6,678 Interest cost 866 1,003 1,733 1,990 Expected return on plan assets (861 ) (942 ) (1,714 ) (1,870 ) Amortization of prior service costs — 20 — 40 Amortization of actuarial losses 232 173 455 345 $ 4,488 $ 3,645 $ 8,339 $ 7,183
Summary of Severance Associated with Cost Reduction Programs	The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2014 $ 6,274 Expense, net of reversals (607 ) Payments (1,510 ) Foreign currency translation (21 ) Balance at June 30, 2015 $ 4,136

Comprehensive Income (Tables)

Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Marketable Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2014 $ (55,740 ) $ (272 ) $ (19,059 ) $ (14,519 ) $ 30,499 $ (59,091 ) Other comprehensive (loss) income before reclassifications (19,670 ) (246 ) (933 ) — 3,473 (17,376 ) Reclassification adjustments — — 10,584 455 (3,414 ) 7,625 Balance at June 30, 2015 $ (75,410 ) $ (518 ) $ (9,408 ) $ (14,064 ) $ 30,558 $ (68,842 )
Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Reclassification Adjustments Affected Financial Statement Line Item Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 Marketable securities Other (income) expense, net $ — $ — $ — $ (5,004 ) Total before income taxes — — — (5,004 ) Income tax expense — — — (1,927 ) Total net of income taxes $ — $ — $ — $ (3,077 ) Derivative instruments: Interest rate swaps Interest expense $ 3,090 $ 3,115 $ 6,103 $ 6,195 Foreign exchange forward contracts Service revenues 2,002 (2,258 ) 4,481 (4,169 ) Total before income taxes 5,092 857 10,584 2,026 Income tax benefit 1,590 736 3,246 1,530 Total net of income taxes $ 3,502 $ 121 $ 7,338 $ 496 Defined benefit plans: Amortization of prior service costs See Note 11 $ — $ 20 $ — $ 40 Amortization of actuarial losses See Note 11 232 173 455 345 Total before income taxes 232 193 455 385 Income tax benefit 85 72 168 144 Total net of income taxes $ 147 $ 121 $ 287 $ 241

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Information presented below is in thousands: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Service revenues Product Development $ 786,397 $ 781,187 $ 1,535,926 $ 1,552,015 Integrated Healthcare Services 287,969 254,289 568,414 488,749 Total service revenues 1,074,366 1,035,476 2,104,340 2,040,764 Costs of revenue, service costs Product Development 453,450 465,278 890,872 915,761 Integrated Healthcare Services 230,395 209,236 454,800 402,475 Total costs of revenue, service costs 683,845 674,514 1,345,672 1,318,236 Selling, general and administrative Product Development 156,777 157,552 311,885 317,237 Integrated Healthcare Services 38,845 33,346 76,767 65,622 General corporate and unallocated 30,276 28,116 56,852 55,397 Total selling, general and administrative 225,898 219,014 445,504 438,256 Income from operations Product Development 176,170 158,357 333,169 319,017 Integrated Healthcare Services 18,729 11,707 36,847 20,652 General corporate and unallocated (30,276 ) (28,116 ) (56,852 ) (55,397 ) Restructuring costs (6,234 ) (948 ) (11,558 ) (1,956 ) Total income from operations $ 158,389 $ 141,000 $ 301,606 $ 282,316
Depreciation and Amortization Expense	Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Depreciation and amortization expense Product Development $ 23,553 $ 23,791 $ 47,429 $ 46,761 Integrated Healthcare Services 5,171 4,854 10,379 9,745 General corporate and unallocated 1,287 1,200 2,532 2,427 Total depreciation and amortization expense $ 30,011 $ 29,845 $ 60,340 $ 58,933

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Stock Options Excluded from Computation of Diluted Earnings Per Share	The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Weighted average shares subject to anti-dilutive share-based awards 1,182 1,598 1,112 1,182

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Additional Information (Detail) - HUYA Bioscience International, LLC [Member] - USD ($)	1 Months Ended
	Feb. 28, 2015	Jan. 31, 2010
Summary of Significant Accounting Policies [Line Items]
Additional consideration agreement		$ 16,500,000
Gain on termination of collaboration agreement	$ 5,000,000
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Related party fund to research and development activity		$ 2,300,000

Employee Stock Compensation - S

Employee Stock Compensation - Schedule of Share-Based Awards Granted and Outstanding (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	53,200	335,100	976,900	1,359,600
Stock options outstanding	7,548,947		7,548,947		9,124,954
Stock Appreciation Rights Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock appreciation rights granted			176,200	176,800
Stock appreciation rights outstanding	557,513		557,513		418,801
Restricted Stock Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock appreciation rights granted	10,389	36,500	237,210	36,500
Stock appreciation rights outstanding	328,611		328,611		93,667
Performance Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock appreciation rights granted			51,977
Stock appreciation rights outstanding	51,977		51,977

Employee Stock Compensation - A

Employee Stock Compensation - Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected volatility, Minimum	28.00%	31.00%	28.00%	31.00%
Expected volatility, Maximum	37.00%	43.00%	41.00%	43.00%
Weighted average expected volatility	31.00%	37.00%	35.00%	37.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Risk-free interest rate, Minimum	1.16%	1.15%	1.06%	0.99%
Risk-free interest rate, Maximum	2.00%	2.13%	2.00%	2.21%
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	3 years 8 months 12 days	3 years 8 months 12 days	3 years 8 months 12 days	3 years 8 months 12 days
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	6 years 8 months 12 days	6 years 8 months 12 days	6 years 8 months 12 days	6 years 8 months 12 days

Employee Stock Compensation -38

Employee Stock Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation expense	$ 10,700	$ 8,400	$ 20,321	$ 15,601
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee stock purchase plan payroll deductions percent	10.00%		10.00%
Discount on closing price of share			15.00%
Common stock shares purchase			38,449

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - Customer	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Concentration Risk [Line Items]
Number of customers served	0	0	0	0
Customer Concentration Risk [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Percentage of service revenue from major customers	10.00%	10.00%	10.00%	10.00%

Accounts Receivable and Unbil40

Accounts Receivable and Unbilled Services - Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Trade:
Billed	$ 506,239	$ 444,941
Unbilled services	584,851	532,312
Trade accounts receivable and unbilled services, gross	1,091,090	977,253
Allowance for doubtful accounts	(1,651)	(1,998)
Trade accounts receivable and unbilled services, net	$ 1,089,439	$ 975,255

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill by Segment (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Goodwill [Line Items]
Beginning Balance	$ 464,434
Impact of foreign currency fluctuations and other	(824)
Ending Balance	463,610
Product Development [Member]
Goodwill [Line Items]
Beginning Balance	346,608
Impact of foreign currency fluctuations and other	(257)
Ending Balance	346,351
Integrated Healthcare Services [Member]
Goodwill [Line Items]
Beginning Balance	117,826
Impact of foreign currency fluctuations and other	(567)
Ending Balance	$ 117,259

Derivatives - Additional Inform

Derivatives - Additional Information (Detail)	1 Months Ended	6 Months Ended
	May. 31, 2015USD ($)	Jun. 30, 2015USD ($)Derivative	Jun. 03, 2015USD ($)Agreement	Jun. 09, 2011Agreement
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative fixed interest rate		2.10%
Interest rate cash flow hedge loss to be reclassified during next 12 months, net		$ 0
Senior Notes [Member] | Fixed Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent		50.00%
Senior Notes [Member] | Variable Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent		50.00%
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Derivative		15
Notional amount		$ 100,600,000
Expiration description of hedge instruments		2015 and the first three months of 2016
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Agreement			7	6
Notional amount			$ 440,000,000
Payment to terminate hedge accounting	$ 12,400,000
Interest rate cash flow hedge loss to be reclassified during next nine months, net		$ (9,300,000)
Interest swaps accrual beginning date		Jun. 30, 2016
Interest Rate Swaps [Member] | Accrued Interest [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Payment to terminate hedge accounting	$ 1,400,000
Interest Rate Swaps [Member] | Minimum [Member] | Six Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Sep. 30, 2013
Interest Rate Swaps [Member] | Minimum [Member] | Seven Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Mar. 31, 2017
Interest Rate Swaps [Member] | Maximum [Member] | Six Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Mar. 31, 2016
Interest Rate Swaps [Member] | Maximum [Member] | Seven Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Mar. 31, 2020

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Other Current Assets [Member] | Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative asset fair value	$ 2,325
Other Current Liabilities [Member] | Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	571	$ 4,635
Other Current Liabilities [Member] | Interest Rate Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 1,832	$ 14,424

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss) (Detail) - Derivatives Designated As Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 8,863	$ 1,802	$ 9,651	$ 3,168
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	8,078	(335)	6,389	(1,144)
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 785	$ 2,137	$ 3,262	$ 4,312

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring Fair Value Measurements [Member] $ in Thousands	Jun. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	$ 2,910
Fair value of liabilities	9,741
Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	2,325
Fair value of liabilities	571
Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	1,832
Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	7,338
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	585
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	2,325
Fair value of liabilities	2,403
Level 2 [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	2,325
Fair value of liabilities	571
Level 2 [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	1,832
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	7,338
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	7,338
Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	585
Marketable Equity Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	$ 585

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Accounts Payable and Accrued Expenses and Other Liabilities [Member] - Contingent Consideration [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance, Contingent Consideration	$ 1,452	$ 13,014
Revaluations included in earnings	5,886	186
Ending Balance, Contingent Consideration	$ 7,338	$ 13,200

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other identifiable intangibles, net	$ 263,217	$ 280,243
Non-recurring Fair Value Measurements [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	797,900
Cost and equity method investments	71,100
Goodwill	463,600
Other identifiable intangibles, net	263,200
Non-recurring Fair Value Measurements [Member] | Level 3 [Member] | Equity Method Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unfunded cash commitments	$ 41,600

Credit Arrangements - Summary o

Credit Arrangements - Summary of Credit Facilities (Detail) - Jun. 30, 2015	USD ($)	EUR (€)
First Lien Revolving Credit Facility [Member]
Credit Facility [Line Items]
Facility	$ 500,000,000
Interest Rate Description	London Interbank Offer Rate (“LIBOR”) (0.28% at June 30, 2015) plus 1.75%
First Lien Revolving Credit Facility [Member] | Minimum [Member]
Credit Facility [Line Items]
Interest Rate spread on base rate	0.85%
First Lien Revolving Credit Facility [Member] | Maximum [Member]
Credit Facility [Line Items]
Interest Rate spread on base rate	1.35%
First Lien Revolving Credit Facility [Member] | LIBOR [Member]
Credit Facility [Line Items]
Rate	0.28%	0.28%
Interest Rate spread on base rate	1.75%
Receivables Financing Facility [Member]
Credit Facility [Line Items]
Facility	$ 25,000,000
Interest Rate Description	LIBOR Market Index Rate (0.19% at June 30, 2015) plus 0.85% to 1.35% depending upon the Company’s debt rating
Rate	0.19%	0.19%
Receivables Financing Facility [Member] | LIBOR [Member]
Credit Facility [Line Items]
Rate	1.24%	1.24%
Receivables Financing Facility [Member] | LIBOR [Member] | Minimum [Member]
Credit Facility [Line Items]
Interest Rate spread on base rate	0.19%
Receivables Financing Facility [Member] | LIBOR [Member] | Maximum [Member]
Credit Facility [Line Items]
Interest Rate spread on base rate	1.05%
General Banking Facility [Member]
Credit Facility [Line Items]
Facility	$ 15,700,000	€ 10,000,000
Interest Rate Description	Bank’s base rate (0.5% at June 30, 2015) plus 1%
General Banking Facility [Member] | Base Rate
Credit Facility [Line Items]
Rate	0.50%	0.50%
Interest Rate spread on base rate	1.00%

Credit Arrangements - Additiona

Credit Arrangements - Additional Information (Detail) £ in Millions	May. 12, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2015GBP (£)	Jun. 30, 2015EUR (€)	Dec. 31, 2014USD ($)
Credit Facility [Line Items]
Outstanding borrowings		$ 0	$ 0			$ 0
Loss on extinguishment of debt		7,780,000	7,780,000
Unamortized debt issuance cost		9,469,000	9,469,000			9,879,000
Unamortized discount		$ 26,072,000	$ 26,072,000			$ 12,379,000
Debt Instrument, covenant description			The Company’s long-term debt agreements contain usual and customary restrictive covenants that, among other things, place limitations on its ability to declare dividends and make other restricted payments; prepay, redeem or purchase debt; incur liens; make loans and investments; incur additional indebtedness; amend or otherwise alter debt and other material documents; engage in mergers, acquisitions and asset sales; transact with affiliates; and engage in businesses that are not related to the Company’s existing business.	The Company’s long-term debt agreements contain usual and customary restrictive covenants that, among other things, place limitations on its ability to declare dividends and make other restricted payments; prepay, redeem or purchase debt; incur liens; make loans and investments; incur additional indebtedness; amend or otherwise alter debt and other material documents; engage in mergers, acquisitions and asset sales; transact with affiliates; and engage in businesses that are not related to the Company’s existing business.
Senior Notes [Member]
Credit Facility [Line Items]
Debt Instrument payment frequency			Interest on the Senior Notes is paid semiannually on May 15 and November 15 (beginning November 15, 2015) of each year until maturity.	Interest on the Senior Notes is paid semiannually on May 15 and November 15 (beginning November 15, 2015) of each year until maturity.
Date of first required debt repayment		Nov. 15, 2015
General Banking Facility [Member]
Credit Facility [Line Items]
Bank guarantees			$ 6,000,000	£ 3.8
Aggregate maximum principal amount		$ 15,700,000	15,700,000		€ 10,000,000
Senior Secured Credit Facilities
Credit Facility [Line Items]
Aggregate maximum principal amount	$ 1,950,000,000
Percentage of excess cash flow for loan repayment	25.00%
Percentage of equity interest of domestic subsidiaries pledged as collateral	100.00%
Percentage of equity interest of foreign subsidiaries pledged as collateral	65.00%
Percentage of repayment from cash proceeds of asset disposition	100.00%
Loss on extinguishment of debt			7,780,000
Unamortized debt issuance cost		1,100,000	1,100,000
Unamortized discount		1,300,000	1,300,000
Fees and expenses		$ 5,400,000	$ 5,400,000
Senior Secured Credit Facilities | Minimum [Member]
Credit Facility [Line Items]
Percentage of excess cash flow for loan repayment	0.00%
Senior Secured Credit Facilities | New Revolver [Member]
Credit Facility [Line Items]
Aggregate maximum principal amount	$ 500,000,000
Credit facility maturity period			5 years	5 years
Senior Secured Credit Facilities | Term Loans [Member]
Credit Facility [Line Items]
Aggregate maximum principal amount	$ 1,450,000,000
Term Loan A [Member]
Credit Facility [Line Items]
Annual Maturities Percentage	5.00%
Term Loan A [Member] | Term Loans [Member]
Credit Facility [Line Items]
Aggregate maximum principal amount	$ 850,000,000
Debt maturity year			2,020	2,020
Term Loan B [Member]
Credit Facility [Line Items]
Annual Maturities Percentage	1.00%
Term Loan B [Member] | Term Loans [Member]
Credit Facility [Line Items]
Aggregate maximum principal amount	$ 600,000,000
Debt maturity year			2,022	2,022
4.875% Senior Notes [Member] | Due in 2023 [Member]
Credit Facility [Line Items]
Debt maturity year			2,023	2,023
Notes issued in private placement, amount	$ 800,000,000
Debt instrument interest rate stated percentage	4.875%	4.875%	4.875%		4.875%
Term Loan A and B [Member]
Credit Facility [Line Items]
Term loan maturity dates, description			Annual maturities on the Term Loan A and the Term Loan B are 5% and 1%, respectively, of the respective original principal amount with the remaining balance to be repaid on their respective maturity dates	Annual maturities on the Term Loan A and the Term Loan B are 5% and 1%, respectively, of the respective original principal amount with the remaining balance to be repaid on their respective maturity dates
Percentage of excess cash flow for loan repayment	50.00%
Term Loan B-3 [Member] | Due in 2018 [Member]
Credit Facility [Line Items]
Debt maturity year			2,018	2,018
Termination of interest rate swaps			$ 11,000,000

Credit Arrangements - Schedule

Credit Arrangements - Schedule of Long-term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Contractual maturities of long-term debt, Total	$ 2,525,000	$ 2,305,606
Less: unamortized discount	(26,072)	(12,379)
Less: unamortized debt issuance costs	(9,469)	(9,879)
Less: current portion	(48,500)	(750)
Long term debt, total	2,440,959	2,282,598
4.875% Senior Notes [Member] | Due in 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	800,000
Term Loan A [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Long-term debt	850,000
Term Loan B [Member] | Due in 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	600,000
Term Loan B-3 [Member] | Due in 2018 [Member]
Debt Instrument [Line Items]
Long-term debt		2,030,606
Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 275,000	$ 275,000

Credit Arrangements - Schedul51

Credit Arrangements - Schedule of Long-term Debt (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2015	May. 12, 2015
4.875% Senior Notes [Member] | Due in 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	4.875%	4.875%
Debt maturity year	2,023
Term Loan A [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,020
Debt instrument interest rate terms, Description	LIBOR plus 1.75%, or 2.03% at June 30, 2015
Term Loan B [Member] | Due in 2022 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,022
Debt instrument interest rate terms, Description	The greater of LIBOR or 0.75% plus 2.50%, or 3.25% at June 30, 2015
Term Loan B-3 [Member] | Due in 2018 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,018
Debt instrument interest rate terms, Description	The greater of three month LIBOR or 1.25% plus 2.50%, or 3.75% at December 31, 2014
Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	0.19%
Debt maturity year	2,018
Debt instrument interest rate terms, Description	LIBOR 0.19% plus 1.05%, or 1.24% at June 30, 2015
LIBOR [Member] | Term Loan A [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	2.03%
Interest Rate spread on base rate	1.75%
LIBOR [Member] | Term Loan B [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	3.25%
LIBOR [Member] | Term Loan B-3 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	3.75%
LIBOR [Member] | Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	1.24%
LIBOR [Member] | Minimum [Member] | Term Loan B [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	0.75%
LIBOR [Member] | Minimum [Member] | Term Loan B-3 [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	1.25%
LIBOR [Member] | Minimum [Member] | Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	0.19%
LIBOR [Member] | Maximum [Member] | Term Loan B [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	2.50%
LIBOR [Member] | Maximum [Member] | Term Loan B-3 [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	2.50%
LIBOR [Member] | Maximum [Member] | Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	1.05%

Credit Arrangements - Contractu

Credit Arrangements - Contractual Maturities of Long-term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
2,015	$ 24,250
2,016	48,500
2,017	48,500
2,018	323,500
2,019	48,500
2,020	664,750
Thereafter	1,367,000
Contractual maturities of long-term debt, Total	$ 2,525,000	$ 2,305,606

Shareholders' Deficit - Additio

Shareholders' Deficit - Additional Information (Detail) - USD ($)	May. 19, 2015	Apr. 30, 2015	Jun. 30, 2015	Oct. 30, 2013
Equity [Abstract]
Equity repurchase program authorized amount				$ 125,000,000
Equity repurchase program increase in authorized amount		$ 300,000,000
Repurchase of common stock, Shares	3,855,050
Repurchase of common stock, value	$ 250,000,000
Repurchase of common stock, share price	$ 64.85
Equity available for repurchase under the repurchase program			$ 109,500,000

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($)	3 Months Ended		5 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Feb. 28, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 6,234,000	$ 948,000		$ 11,558,000	$ 1,956,000
2015 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved						$ 30,000,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 8,100,000
2015 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			2,500,000
2015 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 396,000

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			$ 6,083
Restructuring costs	$ 6,234	$ 948	11,558	$ 1,956
Adjustment for deferred rent			594
Payments			(10,825)
Foreign currency translation			(57)
Restructuring reserves, ending balance	7,353		7,353
Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			5,478
Restructuring costs			10,664
Payments			(10,354)
Foreign currency translation			(57)
Restructuring reserves, ending balance	5,731		5,731
Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			605
Restructuring costs			894
Adjustment for deferred rent			594
Payments			(471)
Restructuring reserves, ending balance	$ 1,622		$ 1,622

Employee Benefit Plans - Summar

Employee Benefit Plans - Summary of Components of Pension Expenses Related to Defined Benefit Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Compensation And Retirement Disclosure [Abstract]
Service cost	$ 4,251	$ 3,391	$ 7,865	$ 6,678
Interest cost	866	1,003	1,733	1,990
Expected return on plan assets	(861)	(942)	(1,714)	(1,870)
Amortization of prior service costs		20		40
Amortization of actuarial losses	232	173	455	345
Total pension expense related to defined benefit plans	$ 4,488	$ 3,645	$ 8,339	$ 7,183

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2015USD ($)Position	Dec. 31, 2014USD ($)
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expenses payable	$ 4,136,000	$ 6,274,000
Number of positions expected to be eliminated | Position	270
Severance expense, net of reversals	$ 607,000
Product Development [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	581,000
Integrated Healthcare Services [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	$ 26,000

Employee Benefit Plans - Summ58

Employee Benefit Plans - Summary of Severance Associated with Cost Reduction Programs (Detail)	6 Months Ended
	Jun. 30, 2015USD ($)
Compensation And Retirement Disclosure [Abstract]
Severance expenses payable, opening balance	$ 6,274,000
Severance expense, net of reversals	(607,000)
Severance payments	(1,510,000)
Severance foreign currency translation	(21,000)
Severance expenses payable, ending balance	$ 4,136,000

Comprehensive Income - Summary

Comprehensive Income - Summary of Components of AOCI (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ (704,061)
Ending Balance	(701,756)
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(55,740)
Other comprehensive (loss) income before reclassifications, before tax	(19,670)
Ending Balance	(75,410)
Marketable Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(272)
Other comprehensive (loss) income before reclassifications, before tax	(246)
Ending Balance	(518)
Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(19,059)
Other comprehensive (loss) income before reclassifications, before tax	(933)
Reclassification adjustments, before tax	10,584
Ending Balance	(9,408)
Defined Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(14,519)
Reclassification adjustments, before tax	455
Ending Balance	(14,064)
Income Taxes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	30,499
Other comprehensive (loss) income before reclassifications, tax	3,473
Reclassification adjustments, tax	(3,414)
Ending Balance	30,558
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(59,091)
Other comprehensive (loss) income before reclassifications, net of tax	(17,376)
Reclassification adjustments, net of tax	7,625
Ending Balance	$ (68,842)

Comprehensive Income - Summar60

Comprehensive Income - Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other expense (income), net	$ 11,659	$ 3,056	$ 8,798	$ (1,788)
Total before income taxes				(5,004)
Income tax expense				(1,927)
Total net of income taxes				(3,077)
Interest expense	(25,487)	(24,799)	(50,827)	(49,502)
Service revenues	(1,074,366)	(1,035,476)	(2,104,340)	(2,040,764)
Total before income taxes	5,092	857	10,584	2,026
Income tax benefit	1,590	736	3,246	1,530
Total net of income taxes	3,502	121	7,338	496
Amortization of prior service costs		20		40
Amortization of actuarial losses	232	173	455	345
Total before income taxes	232	193	455	385
Income tax benefit	85	72	168	144
Total net of income taxes	147	121	287	241
Other Nonoperating Income (Expense) [Member] | Marketable Securities [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other expense (income), net				(5,004)
Other Nonoperating Income (Expense) [Member] | Derivative Instruments [Member] | Interest Rate Swaps [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense	3,090	3,115	6,103	6,195
Other Nonoperating Income (Expense) [Member] | Derivative Instruments [Member] | Foreign Exchange Forward Contracts [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Service revenues	$ 2,002	$ (2,258)	$ 4,481	$ (4,169)

Segments - Additional Informati

Segments - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2015Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Service revenues	$ 1,074,366	$ 1,035,476	$ 2,104,340	$ 2,040,764
Costs of revenue, service costs	683,845	674,514	1,345,672	1,318,236
Selling, general and administrative	225,898	219,014	445,504	438,256
Income from operations	158,389	141,000	301,606	282,316
Restructuring costs	(6,234)	(948)	(11,558)	(1,956)
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Service revenues	786,397	781,187	1,535,926	1,552,015
Costs of revenue, service costs	453,450	465,278	890,872	915,761
Selling, general and administrative	156,777	157,552	311,885	317,237
Income from operations	176,170	158,357	333,169	319,017
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Service revenues	287,969	254,289	568,414	488,749
Costs of revenue, service costs	230,395	209,236	454,800	402,475
Selling, general and administrative	38,845	33,346	76,767	65,622
Income from operations	18,729	11,707	36,847	20,652
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	30,276	28,116	56,852	55,397
Income from operations	$ (30,276)	$ (28,116)	$ (56,852)	$ (55,397)

Segments - Depreciation and Amo

Segments - Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$ 30,011	$ 29,845	$ 60,340	$ 58,933
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	23,553	23,791	47,429	46,761
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	5,171	4,854	10,379	9,745
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$ 1,287	$ 1,200	$ 2,532	$ 2,427

Earnings Per Share - Summary of

Earnings Per Share - Summary of Weighted-Average Outstanding Share-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based awards [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares subject to anti-dilutive share-based awards	1,182	1,598	1,112	1,182

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Subsequent Event [Member]	Jul. 01, 2015
Subsequent Event [Line Items]
Clinical trials laboratory ownership percentage owned by the company	60.00%
Quest [Member]
Subsequent Event [Line Items]
Clinical trials laboratory ownership percentage owned by noncontrolling owners	40.00%